Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RIBBON-1: Bevacizumab + Chemotherapy in Metastatic Breast Cancer
NCT00262067Phase 3Unknown
- Sponsor
- Genentech
- Start
- Dec 2005
- Primary completion
- Jul 2008
- Modality
- Monoclonal Antibodies
- Countries
- 22
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing Bevacizumab + Chemotherapy with Placebo + Chemotherapy (2 arms). Primary endpoint: Progression-free Survival. Status: unknown.
02
Drugs
bevacizumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00262067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00262067.